Dr. Badani discusses PSMA-targeting agents in prostate cancer

"Results showed that more than two-thirds of these men were found to have positive Posluma scans, with a quarter of them having extrapelvic lesions," says Ashesh B. Jani, MD, MSEE, FASTRO.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

"The reported bpMRI-based AI model detected the majority of locally recurrent prostate cancer after radiotherapy," the authors wrote in their study conclusion.

“Implementation of the most recent PI-RADS update did not improve the incongruence in prostate cancer grade assessment between MRI/ultrasound fusion targeted biopsy and surgery,” the authors wrote.

The reimbursement code for flotufolastat F 18 will be effective October 1, 2023.

An exclusive Urology Times survey measured US-based urologists’ uptake, access to, and indications for utilizing prostate-specific membrane antigen-targeting agents.